NCT06195709 2026-04-17
ECLECTIC
Institut Curie
Phase 3 Recruiting
Clinical Trials
62 trialsNCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07205822 2026-04-17
TB06
AstraZeneca
Phase 3 Recruiting
NCT06072612 2026-04-07
BRIA-ABC
BriaCell Therapeutics Corporation
Phase 3 Recruiting
NCT06500455 2026-04-03
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT06103864 2026-03-31
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca
Phase 3 Recruiting
NCT01613482 2026-03-16
TSARINE
Centre Oscar Lambret
Phase 3 Terminated
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT04784715 2026-02-20
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
NCT06757634 2026-02-05
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT05104866 2026-02-04
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT05374512 2026-01-27
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT04964934 2026-01-16
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02297438 2025-10-27
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04158362 2025-09-22
AMBRE
UNICANCER
Phase 3 Active not recruiting
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05552001 2025-06-11
ISIdE
UNICANCER
Phase 3 Recruiting
NCT04588246 2025-06-06
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04799249 2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3 Completed
NCT03423199 2024-03-22
PATHWAY
National Cancer Center, Japan
Phase 3 Unknown
NCT00128310 2023-05-31
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT00377156 2022-09-16
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT00039780 2022-07-13
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT03326674 2021-07-30
CONTESSA
Odonate Therapeutics, Inc.
Phase 3 Terminated
NCT00080301 2020-11-02
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
Phase 3 Completed
NCT01610284 2020-08-25
BELLE-2
Novartis
Phase 3 Completed
NCT01917279 2020-07-23
CAMELLIA
ChineseAMS
Phase 3 Unknown
NCT01091168 2019-09-16
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT00130494 2019-04-16
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Spanish Breast Cancer Research Group
Phase 3 Terminated
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT02929576 2018-10-22
ENDEAR
Pfizer
Phase 3 Withdrawn
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00561119 2017-05-01
Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer
Samsung Medical Center
Phase 3 Completed
NCT00190489 2016-09-02
A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
Japan Clinical Oncology Group
Phase 3 Completed
NCT00293540 2016-07-27
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
International Breast Cancer Research Foundation
Phase 3 Completed
NCT02383030 2016-06-15
FUMANCE
Consorzio Oncotech
Phase 3 Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT00003162 2015-11-17
Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00109239 2014-06-18
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer
Genentech, Inc.
Phase 3 Completed